Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05117840 · ClinicalTrials.gov registry record
Screening for High Frequency Malignant Disease
A clinical trial of Lung Cancer, sponsored by Guardant Health.
- Active
- Registry status
- 12,000
- Enrollment target
- 20
- Study locations
NCT05117840: Active study of Lung Cancer, sponsored by Guardant Health.
NCT05117840 is a study of Lung Cancer that is active but no longer recruiting, run by Guardant Health. The registered enrollment target is 12,000 participants, above the 906-participant average among 409 other Lung Cancer trials with a reported enrollment target (1225% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05117840, a study of Lung Cancer, is active but no longer recruiting, sponsored by Guardant Health.
- ACTIVE NOT RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Primary Outcome
Sensitivity, specificity, NPV, PPV
Conditions Studied
Interventions
- DEVICE Low-dose CT scan
Study Locations (20)
Florida
- Central Florida Pulmonary Group, P.A. - Altamonte Springs
- Pulmonary, Critical Care & Sleep Disorders Institute of South Florida - Atlantis
- CTMD Research - Coconut Creek
- Life Arc Research Centers - Coral Gables
- Pulmonary Physicians of South Florida, LLC - Coral Springs
- SIMED Health, LLC - Gainesville
- National Research Institute - Hialeah
- 3Sync Research - Hialeah
- Zenith Clinical Research - Hollywood
California
- Pacific Cancer Medical Center - Anaheim
- Providence St. Joseph Hospital Eureka Cancer Program - Eureka
- SoCal Clinical Research - Fountain Valley
- Advanced Investigative Medicine - Hawthorne
- Cedars-Sinai Medical Center - Los Angeles
- California Medical Research Associates Inc. - Northridge
- Providence Medical Foundation - Santa Rosa
Alabama
- University of Alabama Birmingham Lung Health Center - Birmingham
Arkansas
- Highlands Oncology Group PA - Fayetteville
Connecticut
- Starling Physicians - New Britain
District of Columbia
- George Washington University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2026-04-30 |
What the registry record for NCT05117840 still lists
NCT05117840 is an observational study that tracks outcomes without assigning an intervention. Its 12,000 participants enrollment target places it among the larger protocols in the corpus, above the 906-participant average among 409 other Lung Cancer trials with a reported enrollment target (1225% higher).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Low-dose CT scan is the first listed.
NCT05117840 names 20 study sites across 6 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05117840 about?
NCT05117840 is a clinical study titled "Screening for High Frequency Malignant Disease". The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency ca...
What is the current status of trial NCT05117840?
This trial is currently active not recruiting. The enrollment target is 12,000 participants. The study started on 2022-01-13. Estimated completion is 2026-04-30.
What conditions does trial NCT05117840 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT05117840?
The interventions under investigation include: Low-dose CT scan (DEVICE).
Who is sponsoring clinical trial NCT05117840?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05117840 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05117840's enrollment target sits among peer trials
12,000 7th of 409 higher than 403 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI